Exebacase: A Novel Approach to the Treatment of Staphylococcal Infections

Lysins are bacteriophage-derived enzymes that degrade essential components of bacteria. Exebacase (Lysin CF-301) is an attractive antimicrobial agent because it demonstrates rapid bacteriolytic activity against staphylococcal species, including Staphylococcus aureus, has a low resistance profile, er...

Descripción completa

Detalles Bibliográficos
Autor principal: McCarthy, Matthew W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167414/
https://www.ncbi.nlm.nih.gov/pubmed/35175568
http://dx.doi.org/10.1007/s40268-022-00383-6
_version_ 1784720793173753856
author McCarthy, Matthew W.
author_facet McCarthy, Matthew W.
author_sort McCarthy, Matthew W.
collection PubMed
description Lysins are bacteriophage-derived enzymes that degrade essential components of bacteria. Exebacase (Lysin CF-301) is an attractive antimicrobial agent because it demonstrates rapid bacteriolytic activity against staphylococcal species, including Staphylococcus aureus, has a low resistance profile, eradicates biofilms, and acts synergistically with other antibiotics. Combinations including exebacase and standard of care antibiotics represent an alternative to antibiotic monotherapies currently used to treat invasive staphylococcal infections. This manuscript reviews what is known about exebacase and explores how this novel agent may be used in the future to treat human bacterial pathogens.
format Online
Article
Text
id pubmed-9167414
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-91674142022-06-06 Exebacase: A Novel Approach to the Treatment of Staphylococcal Infections McCarthy, Matthew W. Drugs R D Review Article Lysins are bacteriophage-derived enzymes that degrade essential components of bacteria. Exebacase (Lysin CF-301) is an attractive antimicrobial agent because it demonstrates rapid bacteriolytic activity against staphylococcal species, including Staphylococcus aureus, has a low resistance profile, eradicates biofilms, and acts synergistically with other antibiotics. Combinations including exebacase and standard of care antibiotics represent an alternative to antibiotic monotherapies currently used to treat invasive staphylococcal infections. This manuscript reviews what is known about exebacase and explores how this novel agent may be used in the future to treat human bacterial pathogens. Springer International Publishing 2022-02-17 2022-06 /pmc/articles/PMC9167414/ /pubmed/35175568 http://dx.doi.org/10.1007/s40268-022-00383-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Review Article
McCarthy, Matthew W.
Exebacase: A Novel Approach to the Treatment of Staphylococcal Infections
title Exebacase: A Novel Approach to the Treatment of Staphylococcal Infections
title_full Exebacase: A Novel Approach to the Treatment of Staphylococcal Infections
title_fullStr Exebacase: A Novel Approach to the Treatment of Staphylococcal Infections
title_full_unstemmed Exebacase: A Novel Approach to the Treatment of Staphylococcal Infections
title_short Exebacase: A Novel Approach to the Treatment of Staphylococcal Infections
title_sort exebacase: a novel approach to the treatment of staphylococcal infections
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167414/
https://www.ncbi.nlm.nih.gov/pubmed/35175568
http://dx.doi.org/10.1007/s40268-022-00383-6
work_keys_str_mv AT mccarthymattheww exebacaseanovelapproachtothetreatmentofstaphylococcalinfections

Ejemplares similares